Press Releases

Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools.

Feb 09, 2021
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of
Feb 09, 2021
Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT” LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to
Feb 09, 2021
6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancers No complement-mediated toxicities reported LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell
Jan 19, 2021
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.
Dec 03, 2020
Agenus to fulfill FDA feedback for six-month follow-up on late responders LEXINGTON, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to
Nov 25, 2020
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr.